During a live event, Krish Patel, MD, surveyed participants on using bispecific T-cell engagers vs loncastuximab in a patient ...

Updated clinical data in heavily pre-treated, CAR-T naïve patients with B-NHL shows prolonged duration of response, with ...

In addition to the receptor used to locate tumor cells, this treatment adds an element that further enhances the immune ...

A next-generation, anti-CD19 enhanced (or "armored") CAR T-cell product showed promising efficacy and safety in a phase I ...

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Greetings, and welcome to TG Therapeutics First Quarter Conference ...

Cheyney, PA, May, 5 2025 - Navrogen, Inc., a biopharmaceutical company specialized in developing antibody-based therapies for ...

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along with recent ...

TG Therapeutics, Inc.’s TGTX share price has dipped by 12.53%, which has investors questioning if this is right time to buy.

The four anti-CD20 drugs used in the U.S. to treat relapsing MS -- ocrelizumab, ofatumumab, and ublituximab (Briumvi; ...

Our previous data revealed that K+/Na+ cation carriers, including salinomycin, robustly upregulate CD20 antigen levels on the surface of malignant B cells via suppression of c-Myc and FOXO, two ...

Miklos Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies $11,034,982 University of California, San Francisco Mort Cowan Gene ...